Downgrades Neutral Underperform X

GRPH Graphite Bio

BofA Securities

$3 $2

Downgrades Overweight Neutral X

GRPH Graphite Bio

Cantor Fitzgerald

$3

Downgrades Outperform Mkt Perform X

GRPH Graphite Bio

Cowen

Downgrades Buy Neutral X

GRPH Graphite Bio

BTIG Research

Downgrades Buy Neutral X

GRPH Graphite Bio

BofA Securities

$7 $3

Downgrades Outperform Mkt Perform X

GRPH Graphite Bio

BMO Capital Markets

$14 $7

Downgrades Outperform Mkt Perform X

GRPH Graphite Bio

SVB Leerink

$11 $2

Initiated Overweight X

GRPH Graphite Bio

Cantor Fitzgerald

$12

Initiated Outperform X

GRPH Graphite Bio

BMO Capital Markets

$12

GRPH  Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.